Jonathan Raa | Nurphoto | Getty Pictures
Novo Nordisk shares climbed 5% on Thursday morning, based on LSEG knowledge, hitting a contemporary file highs after the Danish pharmaceutical large reported constructive early trial knowledge for a brand new experimental weight reduction drug.
The corporate informed an investor assembly that the Part I trial of its highly-anticipated weight problems drug amycretin confirmed a 13.1% weight reduction in contributors after 12 weeks, based on Reuters. This studying eclipses the 6% loss recorded after a 12-week trial for the corporate’s wildly well-liked weight problems drug Wegovy.
A Part II trial will start within the second half of this 12 months, with outcomes anticipated in early 2026, the corporate mentioned.
Shares of Novo Nordisk, Europe’s largest firm by market cap, have gained greater than 27% because the flip of the 12 months because the prescription drugs large continues to reap the advantages of rampant demand for its flagship Wegovy and Ozempic anti-obesity medicine.
Earlier this week, Novo reported late-stage trial results exhibiting that Ozempic reduce the chance of kidney illness development and dying from kidney or cardiovascular issues by 24% in diabetic sufferers with continual kidney illness.
The outcomes added to mounting proof of the broader well being advantages related to Ozempic and comparable medicine, past weight reduction and Sort 2 diabetes therapy.
Shares of American rival Eli Lilly had been down 1.3% in after hours buying and selling on the again of the information.
